Medtronic to cut up to 900 jobs:
This article was originally published in Clinica
Medtronic said in a regulatory filing that it could lay off up to 900 employees, after the company was severely affected by a slowdown in the US implantable cardioverter defibrillator market. The Fridley, Minneapolis-based firm had previously announced that it was to cut 550 jobs (see Clinica No 1262, p 13) but has now upped this figure to include extra early retirements, voluntary departures and layoffs. As of July, 349 jobs had already been eliminated - the company incurred a $14m charge related to compensation expenses, which will be deducted from earnings for the first quarter of 2008.
You may also be interested in...
At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.
COVID-driven supply shortages were both the cause of and solution to production deficiencies for manufacturers of neuromuscular blocking agents; US FDA is permitting Mylan, Gland, and Fresenius Kabi to distribute vecuronium bromide and rocuronium bromide even though they do not have the ‘paralyzing agent’ warning on the caps since the products are in high demand at ICUs. The appropriately embossed caps were unavailable due to supply chain disruptions caused by the pandemic.
Medtronic has agreed to licensing and development agreements with cash-strapped surgical robotics company Titan receiving payments up to $31m pending certain milestones.